A research note from industry analyst GlobalData concludes that India’s new national insurance scheme Ayushman Bharat has potential to be a “game changer,” while warning that there are “policy issues which need to be addressed by the government to make it sustainable for all the stakeholders.”
The program is designed to cover the hospitalization costs for poorer rural families, and certain occupational categories of urban workers, up to $7,000.
Dubbed “Modicare,” after Indian Prime Minister Narendra Modi, the scheme has been criticized for the amount of money set aside to cover costs, just 200 billion rupees, or around a fifth of 1% of India’s GDP.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze